The maturation and advance of the ophthalmology sector will be fully evident tomorrow as we host the largest Ophthalmology Innovation Summit in its seven-year history.
More than 900 clinicians, investors, and executives will descend upon the Planet Hollywood Hotel in Las Vegas to grab a glimpse of novel new treatments for ophthalmology disorders.
Three dozen biopharmaceutical, medtech, and digital health companies – public and private – will introduce themselves or provide updates to the most influential audience in ophthalmology.
The day remains a must attend event for innovators and entrepreneurs, who will receive invaluable advice on intellectual property protection and monetization while hearing from the leading VCs in ophthalmology.
But OIS also will recognize the maturation of the industry. For the first time, the conference will host a Public Company Showcase – giving the stage to six one-time start-ups that have gone public in recent years.
Following these presentations, OIS Co-Chair Emmett T. Cunningham Jr., MD, PhD, MPH, of Clarus Ventures, will lead a panel of Wall Street’s more adroit analysts in a discussion about market cycles and growth of the ophthalmology sector.
However, the news of the day may come from this year’s plenary address from Brent Saunders, CEO and president of Allergan. Allergan, of course, is flirting with Pfizer, hinting at a combination that could alter one of the more venerable names in ophthalmology.
Later, Saunders will join leaders from Alcon, Valeant/Bausch & Lomb, Johnson & Johnson Vision Care, Carl Zeiss Meditec AG, and Santen in the penultimate “Masters of the Universe” discussion led by James V. Mazzo, chairman and CEO of Acufocus, and OIS Co-Chair William J. Link, PhD, of Versant Ventures.
Co-Chair Gilbert H. Kliman, MD, of InterWest Partners will close out the day-long affair.
To register visit OIS.net or register tomorrow morning at the Planet Hollywood Hotel.